Diagnostics News and Research

RSS

Enigma Diagnostics opens new Regional HQ office in San Diego

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Also in Global Health News: U.S. Ambassador to U.N.; Male circumcision; River blindness in Ecuador; Nursing shortage in Caribbean; Maternal health in Bolivia; Drug-resistant TB in North Korea; Cholera vaccine

Betty King reported to her new position as U.S. ambassador to the U.N. in Geneva on Wednesday, the Associated Press reports. "Washington's Geneva mission had been without an ambassador since Warren W. Tichenor left his post on Jan. 20, 2009 - when Barack Obama was sworn in as president," according to the news service (3/3).

4 Mar 2010

BioMS Medical invests in Spectral Diagnostics securities

BioMS Medical Corp. acquired pursuant to a private placement of units, beneficial ownership and control over 30,000,000 common shares and 15,000,000 common shares purchase warrants of Spectral Diagnostics Inc..

4 Mar 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

BioMS Medical Corp. today reported that Spectral Diagnostics has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.

3 Mar 2010

ASPEX to display game-changing PSEM eXpress analyzer at Pittcon 2010

ASPEX Corporation has been advancing the novel Personal Scanning Electron Microscope (PSEM) platform since its first product generation was released in 1992. Since then, it has been "shifting" where SEMs are traditionally installed, "shifting" when SEMs are utilized in industrial processes, and fundamentally "shifting" how SEMs are identified. Come experience the shift at Pittcon 2010, in Orlando, FL from March 1-4.

3 Mar 2010

Biomagnetics Diagnostics announces accelerated delivery timetable for integrated optical biosensor

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced its accelerated timetable for delivery of the world's first handheld, integrated optical biosensor.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Cleveland HeartLab completes $3.0M fundraising round

Cleveland HeartLab LLC (CHL) today announced that it has completed a $3.0-million fundraising round. The company’s new shareholders include local business leaders, and Glengary LLC, Second Generation Ltd. and Zapis Capital Group LLC.

2 Mar 2010

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.

2 Mar 2010

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

2 Mar 2010

Study results of new PCR technology that reports mutations associated with FXS announced

Asuragen, Inc. announced today the results of a collaborative study with scientists at the M.I.N.D. Institute at the University of California Davis evaluating a new PCR technology that reproducibly reports mutations associated with Fragile X syndrome (FXS).

2 Mar 2010

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

AdMeTech Foundation announced today that its President and CEO Dr. Faina Shtern will testify on March 4 before the U.S. House Committee on Oversight and Government Reform on how health care reform highlights the need for increased funding for research aimed at creating accurate, life-saving diagnostic tools for prostate cancer, which will improve screening, prevention, early detection and reduce health costs.

2 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

MDB Capital Group selects Health Discovery as one of Top 50 “Best and Brightest” companies

Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 “Best and Brightest” companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.

27 Feb 2010

Cotton thread as core material in 'lab-on-chip' devices to detect kidney failure and diabetes

A discovery by Monash University scientists could see humble cotton thread emerge as a core material in low-cost 'lab-on-chip' devices capable of detecting diseases such as kidney failure and diabetes.

27 Feb 2010

Phadia AB plans to provide access for specialists to peanut allergen components

Today, at the 2010 Annual Meeting of The American Academy of Allergy, Asthma & Immunology (AAAAI) Phadia, the world leader in in vitro allergy diagnostics, announced plans to provide access for specialists to peanut allergen components. These plans support Phadia’s goal to expand collaboration with allergy and immunology specialists in order to advance the understanding of the clinical utility of allergen component test results.

27 Feb 2010

CAMH signs licensing agreement with US-based Athena Diagnostics to market new genetic test

For the second time in as many months the Centre for Addiction and Mental Health has signed a licensing agreement with US-based Athena Diagnostics Inc. to market a new genetic test.

From Thermo Fisher Scientific Inc. 26 Feb 2010

Diagnostics News and Research

Enigma Diagnostics opens new Regional HQ office in San Diego

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Also in Global Health News: U.S. Ambassador to U.N.; Male circumcision; River blindness in Ecuador; Nursing shortage in Caribbean; Maternal health in Bolivia; Drug-resistant TB in North Korea; Cholera vaccine

BioMS Medical invests in Spectral Diagnostics securities

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

ASPEX to display game-changing PSEM eXpress analyzer at Pittcon 2010

Biomagnetics Diagnostics announces accelerated delivery timetable for integrated optical biosensor

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Cleveland HeartLab completes $3.0M fundraising round

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Study results of new PCR technology that reports mutations associated with FXS announced

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

Precise immune disturbances leading to Coeliac disease: More insight

MDB Capital Group selects Health Discovery as one of Top 50 “Best and Brightest” companies

Cotton thread as core material in 'lab-on-chip' devices to detect kidney failure and diabetes

Phadia AB plans to provide access for specialists to peanut allergen components

CAMH signs licensing agreement with US-based Athena Diagnostics to market new genetic test

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News